Regulation of dendritic cell maturation in osimertinib-treated lung adenocarcinoma patients

Osimertinib (OSI), a third-generation tyrosine kinase inhibitor (TKI), efficiently benefits lung adenocarcinoma (LUAD) patients with epidermal growth factor receptor (EGFR) mutations. However, combined OSI and immune checkpoint inhibitor in EGFR-mutant patients increases the incidence of interstitia...

Full description

Bibliographic Details

Published in:	Journal of the Formosan Medical Association
Main Authors:	Ming-Fang Wu, Ya-Hsuan Chang, Hsuan-Yu Chen, Chao-Chi Ho, Huei-Wen Chen
Format:	Article
Language:	English
Published:	Elsevier 2023-09-01
Subjects:	Lung adenocarcinoma Osimertinib Dendritic cells CD40 CD83
Online Access:	http://www.sciencedirect.com/science/article/pii/S0929664623001444